BCL9 and neoplasm: Previously, we used the hsBCL9CT-24 inhibitor to block interaction between BCL9 and β-cat, and showed that tumor growth inhibition ratio was higher in immune competent than immune compromised mice, suggesting that Bcl9 expressed by immune cells also mediates the therapeutic effect of Bcl9 knockdown.12 We, therefore, also analyzed MC38 tumor growth in WT and Bcl9–/– full knockout mice.